Product Description
HRS-1167 is a drug candidate from Jiangsu HengRui Medicine for the treatment of Advanced Solid Tumors. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05473624?term=HRS-1167&draw=2&rank=1)
Mechanisms of Action: PARP Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hengrui Pharmaceutical
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: Australia, Canada, China, Germany, Japan, Korea, Spain, United Kingdom, United States
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Ovarian Cancer|Prostate Cancer
Phase 1: Colorectal Cancer|Healthy Volunteers|Oncology Solid Tumor Unspecified|Small Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
jRCT2031240640 | P1 |
Recruiting |
Small Cell Lung Cancer |
2027-10-06 |
|
DDRiver 521 | P1 |
Not yet recruiting |
Small Cell Lung Cancer |
2027-10-06 |
|
jRCT2031240418 | P1 |
Recruiting |
Colorectal Cancer |
2026-04-07 |
|
DDRiver 511 | P1 |
Recruiting |
Colorectal Cancer |
2026-04-07 |